Financial Performance - The company's revenue for Q3 2021 was ¥416,090,491.65, representing a 4.25% increase compared to the same period last year[4] - The net profit attributable to shareholders decreased by 77.14% to ¥9,695,301.07, while the net profit excluding non-recurring gains and losses dropped by 89.20% to ¥3,916,277.66[4] - In the first three quarters of 2021, the company achieved a total revenue of RMB 1,261.48 million, representing a year-on-year growth of 17.97%[20] - The net profit attributable to shareholders for the first three quarters of 2021 was RMB 14.83 million, a decline of 82.19% year-on-year[21] - In Q3 2021, the net profit attributable to shareholders was RMB 9.70 million, down 77.14% year-on-year, primarily due to increased labor costs and initial costs from the commercial production project in Qidong, Jiangsu[21] - The total comprehensive income for Q3 2021 was CNY 14,024,461, compared to CNY 73,509,840 in Q3 2020, reflecting a decline of 81.0%[31] - The basic and diluted earnings per share for Q3 2021 were both CNY 0.03, down from CNY 0.17 in Q3 2020[31] Assets and Liabilities - Total assets increased by 16.94% to ¥4,819,831,851.24 compared to the end of the previous year[4] - Total liabilities rose to ¥2,408,610,396.23 from ¥1,669,193,302.07, marking an increase of about 44%[27] - Total assets amounted to approximately ¥4.12 billion, with a significant increase to ¥4.71 billion after adjustments[38] - Current assets totaled approximately ¥919.88 million, while non-current assets reached approximately ¥3.20 billion[38] - Total liabilities were approximately ¥1.67 billion, with non-current liabilities accounting for about ¥881.59 million[38] Cash Flow - The cash flow from financing activities decreased by 65.68% to ¥47,288,299.37, primarily due to reduced net borrowings and dividend payments during the reporting period[12] - Cash flow from operating activities generated a net amount of CNY 262,135,150.87, an increase of 24.7% from CNY 210,247,510.40 in the previous year[34] - Cash and cash equivalents as of September 30, 2021, were ¥318,619,661.89, compared to ¥259,121,396.09 at the end of 2020, indicating a growth of about 23%[25] - Cash and cash equivalents at the end of Q3 2021 totaled CNY 305,332,809.78, up from CNY 236,978,183.67 at the end of Q3 2020[34] - Investment activities resulted in a net cash outflow of CNY 249,156,566.84, an improvement from a net outflow of CNY 308,190,992.18 in the same period last year[34] Research and Development - Research and development expenses surged by 99.53% to ¥90,982,840.49, indicating increased investment in pharmaceutical R&D and production outsourcing services[11] - Research and development expenses increased significantly to CNY 90,982,840, up 99.5% from CNY 45,599,044 in the same period last year[30] Shareholder Information - The company’s total equity attributable to shareholders decreased by 1.69% to ¥2,386,874,098.93 compared to the end of the previous year[4] - The company’s equity attributable to shareholders decreased from ¥2,427,903,737.42 to ¥2,386,874,098.93, a decline of about 2%[27] - The company’s major shareholder, Yunnan Baben Health Industry Co., Ltd., holds 15.28% of the shares, with 76,342,300 shares pledged[16] - The top ten shareholders collectively hold significant stakes, with the largest shareholder having 15.28% of the total shares[16] Operational Performance - Total operating revenue for the period reached ¥1,261,483,497.11, an increase of approximately 18% compared to ¥1,069,362,339.50 in the previous period[29] - Total operating costs amounted to ¥1,261,078,461.21, up from ¥985,350,121.86, reflecting a significant rise in operational expenses[29] - The company reported a significant increase in sales revenue, with cash received from sales reaching CNY 1,315,426,854.98, compared to CNY 1,065,140,303.11 in the previous year, marking a growth of 23.5%[32] Inventory and Receivables - Accounts receivable decreased to ¥360,671,069.79 from ¥384,470,762.02, showing a reduction of approximately 6%[25] - The company reported a decrease in inventory from ¥54,807,328.19 to ¥64,320,928.92, indicating a change in inventory management strategy[25] - Inventory was valued at approximately ¥54.81 million, suggesting effective inventory control[37] Management and Future Outlook - The company plans to enhance its compensation incentive system to address rising labor costs[21] - The micro-ecological health business is expected to continue growing due to increased market share and customer base[21] - The company experienced a significant increase in management expenses, which rose to CNY 193,356,100.55, compared to CNY 166,708,677.26 in the previous year, reflecting a rise of 15.9%[30] Compliance and Audit - The company has not yet audited the third-quarter report, which may affect the reliability of the financial data presented[40] - The company is in compliance with the new leasing standards, which may impact future financial reporting[40]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with a total revenue of CNY 500 million, representing a 25% year-over-year growth[13]. - The company's operating revenue for the reporting period was ¥845,393,005.46, representing a 26.14% increase compared to ¥670,228,150.02 in the same period last year[19]. - The net profit attributable to shareholders was ¥5,137,861.60, a decrease of 87.43% from ¥40,888,811.58 in the previous year[19]. - The net cash flow from operating activities increased by 46.49% to ¥168,844,202.51, up from ¥115,256,353.71 in the same period last year[19]. - The company reported a total revenue of 1,252.45 million, representing a 7.71% increase compared to the previous period[138]. - The company's net profit attributable to ordinary shareholders was 30.65 million, a decrease of 14.64% from 35.91 million in the previous year[45]. - The company's total equity attributable to shareholders decreased to ¥2,073,501,986.14 from ¥2,148,885,818.22, a decline of approximately 3.5%[191]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30%[13]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[13]. - The company is positioned as a leader in the domestic market for preclinical drug development services, serving over 2,300 global clients[35]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[192]. - The company is expanding its market presence, particularly in the biopharmaceutical sector, with strategic partnerships and investments[142]. Research and Development - New product development includes the launch of two innovative drug candidates, expected to enter clinical trials by Q4 2021[13]. - The company plans to invest CNY 200 million in new technology for drug development over the next two years[13]. - R&D investment surged by 170.27% to ¥58,522,126.45, reflecting the company's commitment to enhancing its research capabilities[59]. - The company has established a comprehensive end-to-end service capability for biopharmaceuticals, covering drug discovery to large-scale production[51]. - The company has delivered over 900 protein products to clients, showcasing its extensive capabilities in biopharmaceutical research and development[52]. Client and Revenue Segments - The CRO/CDMO segment generated revenue of ¥684,162,600, accounting for 81% of total revenue, with preclinical CRO services contributing ¥577,957,800, or 84% of the CRO/CDMO segment[27]. - The micro-ecological health segment achieved revenue of ¥161,600,900, representing 19% of total revenue[30]. - The company expanded its client base in the CRO segment, serving 698 clients in the first half of 2021, with 160 new clients contributing over 50 million yuan in revenue, a 29.5% increase year-on-year[41]. - The company has 55 small molecule CDMO service projects, with 42 in early stages and 10 in late clinical phases, indicating a robust project pipeline[42]. Financial Management and Investments - The company will not distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company has recognized significant goodwill from the acquisition of Shanghai Ruizhi, which may be at risk of impairment if future performance does not meet expectations[88]. - The company has a total approved guarantee amount of 139 million yuan, with an actual guarantee balance of 44.593 million yuan, representing 18.77% of the company's net assets[158]. - The company has made a total investment of 13.56 million USD in the pharmaceutical innovation fund as of June 30, 2021[142]. Risks and Challenges - The management highlighted risks including potential declines in service demand and challenges in core technology retention[4]. - The company faces risks from a potential decline in demand for pharmaceutical R&D services, which could significantly impact its business if industry growth trends reverse[84]. - The company has identified risks related to the loss of key scientific and management personnel, which could adversely affect service quality and business operations[85]. - The company is exposed to foreign exchange risks primarily related to USD and EUR, which could pressure profit margins if the RMB appreciates[90]. Environmental and Compliance - The company has established waste management protocols, including hazardous waste storage facilities, to comply with environmental regulations and ensure proper disposal of hazardous materials[106]. - The company has implemented an environmental self-monitoring program, including annual waste gas monitoring and quarterly wastewater and noise monitoring[116]. - The company emphasizes green chemistry initiatives to reduce environmental impact and improve synthesis efficiency[121]. - The company has maintained AAALAC certification for ten consecutive years, ensuring high standards in animal welfare for drug development[126]. Corporate Governance and Shareholder Information - The company has not distributed cash dividends or issued bonus shares during the reporting period, indicating a focus on reinvestment rather than immediate shareholder returns[103]. - The company has not engaged in any violations regarding external guarantees during the reporting period[131]. - The chairman of the company is currently under investigation but continues to perform his duties normally[134]. - The total number of ordinary shareholders at the end of the reporting period was 15,225[169].

睿智医药科技股份有限公司 2021 年第一季度报告全文 睿智医药科技股份有限公司 2021 年第一季度报告 2021 年 04 月 1 睿智医药科技股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪维、主管会计工作负责人辜团力及会计机构负责人(会计主 管人员)辜团力声明：保证季度报告中财务报表的真实、准确、完整。 2 睿智医药科技股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 389,706,314.16 | 278,744,900.86 | 39.81% | | 归属于上市公司股东的净利润（元） | 1,631,770.54 | -14,153, ...

Financial Performance - The company reported a total revenue of 499,776,892, with a cash dividend of 0.7 yuan per 10 shares to all shareholders[5]. - The company's total revenue for 2020 was CNY 1,481,591,872.64, representing an increase of 11.58% compared to 2019[17]. - The net profit attributable to shareholders for 2020 was CNY 154,550,403.78, up by 11.25% from the previous year[17]. - The net cash flow from operating activities increased by 59.56% to CNY 343,160,357.56[17]. - The basic earnings per share for 2020 were CNY 0.31, reflecting a 10.71% increase from 2019[17]. - The company achieved a total revenue of CNY 1,481.59 million in 2020, representing a year-on-year growth of 11.58%[59]. - The net profit attributable to shareholders reached CNY 154.55 million, an increase of 11.25% compared to the previous year[59]. - The pharmaceutical R&D and production services segment generated revenue of CNY 1,213.50 million, up 10.52% year-on-year, with a significant growth of 15.96% in the last three quarters[61]. - The revenue from the micro-ecological nutrition and medical business reached CNY 27,994.20 million, a year-on-year increase of 20.47%[74]. - The company reported a total revenue of 1.54 billion RMB for the year 2020, reflecting a growth of 8% compared to the previous year[169]. Risk Management - The company faces risks including a decline in service demand, loss of core technology and management personnel, and fluctuations in raw material prices[5]. - The company has a detailed section on risks and countermeasures in its operational discussion, highlighting its proactive approach to risk management[5]. - The company is exposed to raw material price fluctuations, particularly for sucrose and lactose, which could affect production costs and profit margins[127]. - The company confirmed a significant amount of goodwill after acquiring Shanghai Ruizhi, which poses a risk of impairment if future performance does not meet expectations[128]. - The company faces foreign exchange risks primarily related to the US dollar and euro, with most service costs denominated in RMB, potentially impacting profit margins[130]. - The company is at risk of losing key scientific and management personnel, which could significantly impact its operations and service quality[124]. - The company is committed to investing in technology R&D to mitigate the risk of new technology development failures[125]. - The company is closely monitoring regulatory compliance to avoid penalties that could harm its reputation and business operations[126]. - The company acknowledges the impact of unforeseen events, such as natural disasters and public health crises, on its operations and is taking steps to mitigate these risks[136]. Operational Strategy - The company has outlined its future plans and performance forecasts, emphasizing the importance of risk awareness among investors[5]. - The company is exploring market expansion opportunities, particularly in overseas markets, to mitigate risks associated with domestic demand[5]. - The company has established three core business divisions: pharmaceutical research services, micro-ecological nutrition, and micro-ecological medical services, to enhance competitiveness and profitability[129]. - The company aims to enhance its CRO/CDMO service platform and increase market share by leveraging its technological advantages and customer reputation[115]. - The company plans to strengthen its domestic pharmaceutical market expansion and optimize its operational system to align with local market needs[116]. - The company is focused on continuous innovation in technology platforms, including the development of DNA-encoded compound libraries and PROTAC technology platforms[121]. - The company is actively involved in research and development collaborations with various related parties to enhance its product offerings[168]. Compliance and Governance - The board of directors has confirmed the accuracy and completeness of the financial report, ensuring accountability for any misleading statements[4]. - The company emphasizes the importance of compliance with regulatory standards in its operations, particularly in drug development and manufacturing[11]. - The company has established a complete corporate governance structure to ensure independent decision-making[146]. - The company has committed to maintaining the independence of its operations and minimizing related party transactions[145]. - The company has ensured that its financial and operational independence is upheld, with no asset occupation by controlling parties[146]. - The company has established a commitment to avoid any related party transactions that could harm the interests of Quantum High-Tech and its shareholders[147]. - The company has implemented measures to ensure that core management personnel sign confidentiality and non-competition agreements[153]. Investment and Growth - The company has invested significant resources in integrating Shanghai Ruizhi to achieve expected synergies and benefits, while facing risks related to liquidity and unforeseen costs[128]. - The company has established a joint investment fund, ShangPharma Capital LP, with a total scale of 100 million USD, where the company contributed 30 million USD, representing 30% of the fund[171]. - The company aims to enhance its core competitiveness by integrating global pharmaceutical industry resources through its investment in the fund[171]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach, with a budget of 500 million yuan set aside for strategic investments[150]. - The company has committed to a lock-up period of 36 months for shares held by key personnel following the IPO[153]. Social Responsibility and Environmental Compliance - The company actively engages in social responsibility initiatives, including participation in global pandemic relief actions[191]. - The company donated over 1 million yuan worth of probiotics to support pandemic relief efforts in Wuhan and other regions[191]. - The company has established a comprehensive quality and environmental health safety (EHS) system in compliance with FDA standards for new drug development[190]. - The company’s waste gas emission concentrations from three outlets were within permissible limits, with the highest concentration being 14.7 mg/m³, well below the maximum allowable of 70 mg/m³[195]. - The company has signed contracts with five licensed hazardous waste disposal units to ensure compliant waste management[196]. Employee and Talent Management - The company has a talent pool of 2,357 employees, with 167 holding doctoral degrees and over 36% possessing a master's degree or higher[54]. - The company intends to attract and manage talent effectively while increasing employee training efforts[116]. - The company has implemented an employee stock option incentive plan, granting 6.73 million stock options to 86 participants[164].

睿智医药科技股份有限公司 2020 年第三季度报告全文 睿智医药科技股份有限公司 2020 年第三季度报告 2020 年 10 月 1 睿智医药科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪维、主管会计工作负责人辜团力及会计机构负责人(会计主 管人员)辜团力声明：保证季度报告中财务报表的真实、准确、完整。 2 睿智医药科技股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,223,948,068.93 | 3,767,716,601.98 | | 12.11% | | 归属于上市公司股东的净资产（元） | 2,364,79 ...

Financial Performance - The company's operating revenue for the current reporting period is ¥670,228,150.02, representing an increase of 8.96% compared to the same period last year[20]. - The net profit attributable to shareholders for the current period is ¥40,888,811.58, showing a decrease of 16.94% year-over-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is ¥30,887,949.98, down 31.92% from the previous year[20]. - The net cash flow from operating activities increased significantly by 160.18%, reaching ¥115,256,353.71[20]. - The total assets at the end of the reporting period are ¥3,956,362,905.28, which is a 5.01% increase from the end of the previous year[20]. - The revenue from pharmaceutical research services and production outsourcing reached ¥522,630,740.19, with a year-on-year increase of 1.69%[86]. - Revenue from micro-ecological nutritional preparations was ¥144,721,272.72, showing a significant year-on-year increase of 50.54%[86]. - Investment income amounted to ¥7,816,070.65, contributing 17.56% to total profit, with sustainable earnings from equity method investments[88]. - The gross profit margin for the first half of 2020 was 29.60%, down from 36.35% in the same period last year[69]. - The company’s operating income was 670.23 million yuan, an 8.96% increase year-on-year, driven by sales growth in the micro-ecological and pharmaceutical R&D services[83]. Risks and Challenges - The company faces risks including a decline in demand for pharmaceutical R&D services, intensified competition, talent loss, and goodwill impairment[5]. - The company is exposed to intensified competition in the global pharmaceutical R&D services market, which may adversely affect its performance[114]. - The company is at risk of losing key clients, which could lead to a significant decline in revenue[116]. - The company faces risks related to regulatory compliance and the potential inability to obtain necessary licenses, which could significantly impact its operations[121]. - The company acknowledges the impact of unforeseen events, such as natural disasters and public health crises like COVID-19, on its operational capabilities[126]. - The company faces foreign exchange risks primarily related to USD and EUR, with a potential impact on profit margins if the RMB appreciates against the USD[121]. Operational Strategies - The report includes a detailed analysis of the company's operational risks and corresponding mitigation strategies[5]. - The company plans to continuously invest in personnel and capital for technology R&D innovation to enhance its core capabilities[117]. - The company is actively integrating Shanghai Ruizhi to enhance competitiveness and profitability, establishing a comprehensive financial reporting and responsibility system[120]. - The company is exploring various measures to mitigate raw material price volatility, including sugar futures hedging and improving production processes[118]. - The company has established a risk management strategy to address potential government regulatory risks in various countries[117]. Market Position and Growth - The company has established itself as the third-largest drug discovery and preclinical research outsourcing service provider in China, and the second-largest in biopharmaceutical R&D outsourcing services[49]. - The global biopharmaceutical R&D services market is projected to grow from $4.8 billion in 2012 to $20 billion by 2021, indicating significant growth potential for biopharmaceutical R&D service providers[55]. - The CDMO/CMO market is projected to grow as small pharmaceutical companies, which accounted for 76.8% of the total in 2019, are expected to rise to 79.1% by 2023, driving innovation[41]. - The company is focusing on enhancing its research and development capabilities to innovate new technologies[146]. - Strategic partnerships and collaborations are being explored to strengthen market presence and operational efficiency[146]. Environmental and Compliance - The company has established a comprehensive environmental protection management system, ensuring compliance with environmental laws and regulations[180]. - The company has implemented self-monitoring programs for environmental protection, including annual air monitoring and quarterly wastewater and noise monitoring[179]. - The company emphasizes green chemistry initiatives, focusing on reducing hazardous chemical usage and improving synthesis efficiency[182]. - The company has made significant investments in environmental protection technologies, enhancing its management and technical capabilities[180]. - The company has established a hazardous waste management system to ensure proper disposal and prevent environmental pollution[183]. Shareholder Information - The company has a total of 499,776,892 shares, with 80.75% being unrestricted shares[191]. - The largest shareholder, Yunnan Babon Health Industry Co., Ltd., holds 16.05% of the shares, totaling 80,199,000 shares, which are pledged[193]. - The second-largest shareholder, Hangzhou Ciyuan Liangjia Investment Management Partnership, holds 11.82% of the shares, totaling 59,094,000 shares[193]. - The total number of common shareholders at the end of the reporting period was 14,560[193]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[195]. Legal and Regulatory Matters - A subsidiary, Kaihui Pharmaceutical, was fined RMB 800,000 for environmental pollution, with an appeal currently in process[135]. - The company believes the lawsuit will not impact its current or future profits[136]. - The total amount involved in the lawsuit against Kaihui Pharmaceutical is RMB 5.8246 million[137]. - The company has not initiated any poverty alleviation programs in the reporting period[186]. - The company has no significant litigation matters other than the aforementioned lawsuit[138].

量子高科（中国）生物股份有限公司 2020 年第一季度报告全文 量子高科（中国）生物股份有限公司 2020 年第一季度报告 2020 年 04 月 1 量子高科（中国）生物股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人曾宪维、主管会计工作负责人辜团力及会计机构负责人(会计主 管人员)辜团力声明：保证季度报告中财务报表的真实、准确、完整。 2 量子高科（中国）生物股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 278,744,900.86 | 297,504,646.00 | -6.31% | | 归属于上市公司股东的净利润（元） | -14,15 ...

量子高科（中国）生物股份有限公司 2019 年年度报告全文 量子高科（中国）生物股份有限公司 2019 年年度报告 2020 年 04 月 - 1 - 量子高科（中国）生物股份有限公司 2019 年年度报告全文 第一节 重要提示、目录和释义 公司存在受新型冠状病毒肺炎疫情影响风险、市场竞争风险、成本费用波 动的风险、境外业务风险、产品质量风险等，敬请广大投资者注意投资风险。 公司在本报告第四节"经营情况讨论与分析"中的"公司面临的风险和应对措 施" 详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关注相关 内容。 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 公司负责人曾宪维、主管会计工作负责人辜团力及会计机构负责人(会计主 管人员)辜团力声明：保证年度报告中财务报告的真实、准确、完整。 - 2 - | 目录 | | --- | 所有董事均已出席了审议本报告的董事会会议。 | 第一节 | 重要提示、目录和释义 | | - 2 - | | -- ...

Financial Performance - Operating revenue decreased by 5.91% to CNY 339,010,498.07 for the current period, but increased by 53.72% to CNY 954,145,831.72 year-to-date[7] - Net profit attributable to shareholders decreased by 45.04% to CNY 31,940,729.91 for the current period, and decreased by 27.76% to CNY 81,171,456.40 year-to-date[7] - Basic earnings per share decreased by 45.06% to CNY 0.0639 for the current period, and decreased by 35.25% to CNY 0.1624 year-to-date[7] - The weighted average return on equity decreased by 1.31% to 1.44% for the current period, and decreased by 5.16% to 3.66% year-to-date[7] - The company's total revenue for Q3 2019 was CNY 339.01 million, a year-on-year decrease of 5.91%[19] - The net profit attributable to ordinary shareholders for Q3 2019 was CNY 31.94 million, a decrease of 45.04% year-on-year, primarily due to increased investment in the Jiangsu Qidong innovative biopharmaceutical R&D platform and higher financial expenses from acquisition loans[20] - The comprehensive income total for Q3 2019 was CNY 35,086,515.89, down 44.5% from CNY 62,859,407.83 in the same quarter last year[39] - The total comprehensive income attributable to the parent company was CNY 35,585,934.20, down from CNY 62,962,035.07 in the previous period, representing a decrease of approximately 43.5%[40] Assets and Liabilities - Total assets increased by 7.82% to CNY 3,609,563,241.24 compared to the end of the previous year[7] - The company's total liabilities reached CNY 1,359,659,757.90, compared to CNY 1,143,195,367.00 at the end of 2018, marking an increase of about 18.9%[30][31] - The company's equity attributable to shareholders increased to CNY 2,237,019,891.90 from CNY 2,190,031,453.40, reflecting a growth of approximately 2.1%[31] - The company's current assets totaled CNY 800,078,419.51, compared to CNY 735,316,120.59 at the end of 2018, reflecting a growth of approximately 8.8%[28][29] - Accounts receivable increased to CNY 440,008,423.78 from CNY 335,589,920.50, representing a rise of about 31.1% year-over-year[28][29] - Inventory levels rose significantly to CNY 79,693,999.20, up from CNY 49,891,639.97, indicating a growth of approximately 59.8%[28][29] - Current liabilities rose to CNY 134,472,447.99, an increase of 52.0% compared to CNY 88,470,155.36 in the previous year[35] Cash Flow and Investments - The net cash flow from operating activities decreased by 46.26% to CNY 82,209,783.00 year-to-date[7] - The cash flow from operating activities generated a net amount of CNY 82,209,783.00, down 46.0% from CNY 152,970,509.37 in the same period last year[53] - Investment activities resulted in a net cash outflow of CNY 131,763,321.06, compared to a net outflow of CNY 903,908,978.07 in the previous year[53] - The company incurred financial expenses of CNY 28,551,119.67, significantly higher than CNY 8,954,222.06 in the same quarter last year[49] - The company received CNY 39,414,715.48 in tax refunds, compared to CNY 5,116,432.74 in the previous year[51] Research and Development - The company's R&D expenses for the first nine months of 2019 were CNY 38.08 million, an increase of 151.15% year-on-year, reflecting ongoing increases in overall R&D investment[17] - Research and development expenses increased to CNY 12,540,040.38, up 51.8% from CNY 8,258,398.78 year-on-year[38] - Research and development expenses were CNY 10,682,314.33, a slight increase from CNY 10,244,947.72 year-over-year[49] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,833[11] - The largest shareholder, Yunnan Babon Health Industry Co., Ltd., holds 16.05% of the shares, totaling 80,199,000 shares[11] - No repurchase transactions were conducted by the top 10 shareholders during the reporting period[12] Other Financial Information - The company received government subsidies amounting to CNY 5,906,992.72 during the reporting period[8] - The company reported no violations regarding external guarantees during the reporting period[23] - There were no overdue commitments from controlling shareholders or related parties during the reporting period[24] - The company has not disclosed any cash dividend policies during the reporting period[23] - The company did not apply new financial instrument standards or new revenue standards for the year 2019[58] - The Q3 2019 report was not audited[58]

量子高科（中国）生物股份有限公司 2019 年半年度报告全文 量子高科（中国）生物股份有限公司 2019 年半年度报告 2019 年 08 月 1 量子高科（中国）生物股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人曾宪经、主管会计工作负责人辜团力及会计机构负责人(会计主 管人员)辜团力声明：保证本半年度报告中财务报告的真实、准确、完整。 本半年度报告中如有涉及未来计划或规划等前瞻性陈述的，均不构成公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告中如有涉及未来计划或规划等前瞻性陈述的，均不构成公司 对投资者的实质承诺，投资者及相关人士均应对此保持足够的风险认识，并且 应当理解计划、预测与承诺之间的差异。 公司存在各业务板块整合及协同效应的风险、商誉减值风险、市场竞争风 险、成本费用波动风险、境外业务风险 ...